{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:57:04Z","timestamp":1786993024341,"version":"build-2736575974"},"reference-count":24,"publisher":"Stanford University Press","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jmsacl.2023.02.009","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T12:51:47Z","timestamp":1678366307000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Evaluating the performance of the Roche FEN2 fentanyl immunoassay and its clinical implementation: The role of LDT-based mass spectrometry testing"],"prefix":"10.21627","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-5713","authenticated-orcid":false,"given":"Marlen","family":"Menlyadiev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Suhandynata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kelner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-8525","authenticated-orcid":false,"given":"Robert L.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4811","reference":[{"issue":"2","key":"10.1016\/j.jmsacl.2023.02.009_b0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/ajcp\/aqz096","article-title":"Regulation of laboratory-developed tests","volume":"152","author":"Genzen","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.02.009_b0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1373\/clinchem.2015.248146","article-title":"Effective use of mass spectrometry in the clinical laboratory","volume":"62","author":"Jannetto","year":"2016","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/j.jmsacl.2023.02.009_b0015","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1373\/clinchem.2014.222976","article-title":"Liquid chromatography high-resolution TOF analysis: investigation of MSE for broad-spectrum drug screening","volume":"60","author":"Chindarkar","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jmsacl.2023.02.009_b0020","doi-asserted-by":"crossref","unstructured":"Metushi IG, Wakefield MR, Lynch K, Stone J, Fitzgerald RL. Reproducibility for a Broad Spectrum Drug Screening Method from Urine using Liquid Chromatography Time-of-Flight Mass Spectrometry. Clin Mass Spec 2018; 8:1-7.19.","DOI":"10.1016\/j.clinms.2018.02.002"},{"issue":"7","key":"10.1016\/j.jmsacl.2023.02.009_b0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jat\/bku075","article-title":"False-positive interferences of common urine drug screen immunoassays: a review","volume":"38","author":"Saitman","year":"2014","journal-title":"J. Anal. Toxicol."},{"issue":"4","key":"10.1016\/j.jmsacl.2023.02.009_b0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.annemergmed.2014.12.019","article-title":"Overdose of etizolam: the abuse and rise of a benzodiazepine analog","volume":"65","author":"O'Connell","year":"2015","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.jmsacl.2023.02.009_b0035","first-page":"bkab103","article-title":"Kreshak AA qua-alluding to the past: a case of methaqualone analog ingestion","volume":"21","author":"Lund","year":"2021","journal-title":"J. Anal. Toxicol."},{"issue":"3","key":"10.1016\/j.jmsacl.2023.02.009_b0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul. Toxicol. Pharm."},{"issue":"4","key":"10.1016\/j.jmsacl.2023.02.009_b0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/BF03178274","article-title":"Transdermal fentanyl: pharmacology and toxicology","volume":"5","author":"Nelson","year":"2009","journal-title":"J. Med. Toxicol."},{"issue":"5","key":"10.1016\/j.jmsacl.2023.02.009_b0050","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40261-016-0394-y","article-title":"Fentanyl buccal soluble film: a review in breakthrough cancer pain","volume":"36","author":"Garnock-Jones","year":"2016","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.jmsacl.2023.02.009_b0055","doi-asserted-by":"crossref","unstructured":"Bernard SA, Chelminski PR, Ives TJ, Ranapurwala SI. Management of Pain in the United States-A Brief History and Implications for the Opioid Epidemic. Health Serv Insights. 2018;11:1178632918819440. Published 2018 Dec 26. 10.1177\/1178632918819440.","DOI":"10.1177\/1178632918819440"},{"issue":"5","key":"10.1016\/j.jmsacl.2023.02.009_b0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10408363.2022.2037122","article-title":"The North American opioid epidemic: opportunities and challenges for clinical laboratories","volume":"59","author":"Delaney","year":"2022","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.jmsacl.2023.02.009_b0065","unstructured":"https:\/\/www.thermofisher.com\/document-connect\/document-connect.html?url=https:\/\/assets.thermofisher.com\/TFS-Assets%2FCDD%2FPackage-Inserts%2F10016007-DRI-Fentanyl-Assay-CJF-EN.pdf."},{"key":"10.1016\/j.jmsacl.2023.02.009_b0070","unstructured":"FEN2 (Fentanyl II Enzyme Immunoassay) Package Insert, V1.0\/2021-11, Roche Diagnostics, 2021."},{"issue":"5","key":"10.1016\/j.jmsacl.2023.02.009_b0075","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/jalm\/jfab033","article-title":"Performance evaluation of an automated fentanyl immunoassay","volume":"6","author":"Tang","year":"2021","journal-title":"J. Appl. Lab. Med."},{"issue":"2","key":"10.1016\/j.jmsacl.2023.02.009_b0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jat\/bkaa053","article-title":"Performance of two fentanyl immunoassays against a liquid chromatography-tandem mass spectrometry method","volume":"45","author":"Feng","year":"2021","journal-title":"J. Anal. Toxicol."},{"issue":"6","key":"10.1016\/j.jmsacl.2023.02.009_b0085","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/jalm\/jfaa048","article-title":"Comparison of two commercially available fentanyl screening immunoassays for clinical use","volume":"5","author":"Budelier","year":"2020","journal-title":"J. Appl. Lab. Med."},{"issue":"1","key":"10.1016\/j.jmsacl.2023.02.009_b0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/clpt.1980.138","article-title":"Intravenous fentanyl kinetics","volume":"28","author":"McClain","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jmsacl.2023.02.009_b0095","unstructured":"Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 10th ed. Biomedical Publications: Seal Beach, California 2014; 846-849."},{"key":"10.1016\/j.jmsacl.2023.02.009_b0100","series-title":"Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline","author":"CLSI","year":"2014"},{"issue":"Pt A","key":"10.1016\/j.jmsacl.2023.02.009_b0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jmsacl.2023.02.009_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108264","article-title":"Fentanyl analog positivity among near-real-time urine drug test results in patients seeking health care","volume":"217","author":"Stanton","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.jmsacl.2023.02.009_b0115","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/jalm\/jfac065","article-title":"An opioid hiding in plain sight: loperamide-induced false-positive fentanyl and buprenorphine immunoassay results","volume":"7","author":"Geno","year":"2022","journal-title":"J. Appl. Lab. Med."},{"issue":"9","key":"10.1016\/j.jmsacl.2023.02.009_b0120","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jat\/bku103","article-title":"Cross-reactivity of acetylfentanyl and risperidone with a fentanyl immunoassay","volume":"38","author":"Wang","year":"2014","journal-title":"J. Anal. Toxicol."}],"container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X23000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X23000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:22:34Z","timestamp":1767770554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667145X23000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"alternative-id":["S2667145X23000160"],"URL":"https:\/\/doi.org\/10.1016\/j.jmsacl.2023.02.009","relation":{},"ISSN":["2667-145X"],"issn-type":[{"value":"2667-145X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the performance of the Roche FEN2 fentanyl immunoassay and its clinical implementation: The role of LDT-based mass spectrometry testing","name":"articletitle","label":"Article Title"},{"value":"Journal of Mass Spectrometry and Advances in the Clinical Lab","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmsacl.2023.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 THE AUTHORS. Publishing services by ELSEVIER B.V. on behalf of MSACL.","name":"copyright","label":"Copyright"}]}}